Projects

  • CRISPR-based studies of pathogenic neutrophil behavior.

  • Identification of drug targets related to autoreactive T cells in the context of autoimmune joint inflammation.

  • Therapeutic antibody treatment for cancer; a role for different myeloid suppressor cells and IL-4R signaling.

  • Studies related to expansion, and CRISPR-based modification of hematopoietic stem cells.

  • Custom CRISPR/Cas9 screens to identify drug targets in inflammatory diseases and cancer.

—

We focus on custom, hypothesis-driven screens enabling performing screens in difficult cells and complex settings with retained discovery potential.

Illustration: Mats Ceder

An overview of our discovery process aiming to identify novel therapeutic interventions in autoimmunity and cancer:

From “Designing custom CRISPR libraries for hypothesis-driven drug target discovery”, Iyer et al., 2020.

Overal setup for CRISPR screens:

From “Designing custom CRISPR libraries for hypothesis-driven drug target discovery”, Iyer et al., 2020.

For rapidly testing different candidate genes, we have developed and extensively use a simple in vitro and in vivo discovery approach that we call RCC (see linked Twitter thread here):

From “A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system”, Shen et al., 2021

Example of how RCC can be used in vitro to identify genes affecting T cell activation:

From “A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system”, Shen et al., 2021